Target Name: MIR5088
NCBI ID: G100847074
Other Name(s): hsa-miR-5088-3p | mir-5088 | hsa-mir-5088 | microRNA 5088 | MicroRNA 5088 | hsa-miR-5088-5p

MIR5088: A Potential Drug Target and Biomarker

MIR5088, a synthetic derivative of the natural compound mesothelin, is a potential drug target and biomarker for various diseases, including cancer. Its unique structure, which consists of a monoclonal antibody targeting the extracellular domain of the protein mesothelin, makes it an attractive candidate for drug development. In this article, we will discuss the structure, synthesis, and potential applications of MIR5088 as a drug target and biomarker.

Structure and Mechanism

MIR5088 is a monoclonal antibody designed to selectively bind to the extracellular domain of the protein mesothelin, a transmembrane glycoprotein that is expressed in various tissues, including the lining of various body surfaces and organs. The extracellular domain of mesothelin is a key region that is involved in cell-cell adhesion, tissue remodeling, and cancer progression.

MIR5088 is synthesized using a variety of techniques, including the synthesis of cell-soluble proteins, the preparation of cell-free protein fusions, and the use of recombinant DNA techniques. The monoclonal antibody is generated by the fusion of a human B cell with a cancer cell to create a cell-free protein that can be used as a target for drugs.

Applications

MIR5088 has a wide range of potential applications as a drug target and biomarker. Its unique structure, which consists of a monoclonal antibody targeting the extracellular domain of mesothelin, makes it an attractive candidate for drug development.

Drug Target

MIR5088 has been shown to be a potential drug target for various diseases, including cancer. Its ability to selectively bind to the extracellular domain of mesothelin makes it an attractive candidate for cancer treatment. MIR5088 has been shown to inhibit the growth of various cancer cell lines, including human breast, lung, and ovarian cancer cells.

Biomarker

MIR5088 has also been shown to be a potential biomarker for various diseases, including cancer. Its ability to bind to the extracellular domain of mesothelin makes it an attractive candidate for cancer diagnosis and monitoring. MIR5088 has been shown to be effective in detecting cancer in a variety of settings, including tissue samples, blood samples, and buffers.

Conclusion

MIR5088 is a unique and promising candidate for drug development as a potential drug target and biomarker for various diseases, including cancer. Its ability to selectively bind to the extracellular domain of mesothelin makes it an attractive candidate for cancer treatment, and its potential as a biomarker for cancer diagnosis and monitoring gives it a high potential for clinical use. Further research is needed to fully understand the potential applications of MIR5088 as a drug target and biomarker.

Protein Name: MicroRNA 5088

More Common Targets

MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193 | MIR5194 | MIR5195 | MIR5196 | MIR5197 | MIR519A1 | MIR519A2 | MIR519B | MIR519C | MIR519D | MIR519E | MIR520A | MIR520B | MIR520C | MIR520D | MIR520E | MIR520F | MIR520G | MIR520H | MIR521-1 | MIR521-2 | MIR522 | MIR523 | MIR524 | MIR525 | MIR526A1 | MIR526A2 | MIR526B | MIR527 | MIR532 | MIR539 | MIR541 | MIR542 | MIR543 | MIR544A | MIR544B | MIR545 | MIR548A1 | MIR548A1HG | MIR548A2 | MIR548A3 | MIR548AA1 | MIR548AA2 | MIR548AC | MIR548AD | MIR548AE1 | MIR548AE2 | MIR548AG1 | MIR548AG2 | MIR548AH | MIR548AI | MIR548AJ1 | MIR548AJ2 | MIR548AL